Genomed
GenoMed is a US preventive-molecular-medicine company using its SNPnet® genomics platform and ACE-inhibitor protocols to deliver a $200/year COIP® subscription for patients with diabetes, hypertension, and emphysema, and to license disease-gene targets to pharmaceutical partners.
- Company typePrivate
- Founded2001
- HeadquartersLeesburg, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Genomed does
GenoMed is a US-based preventive molecular medicine company founded in 2001 by Dr. David Moskowitz on the thesis that the angiotensin I-converting enzyme (ACE) gene acts as a "master disease gene" linked to roughly 160 common conditions. Its core technology platform combines SNPnet®, a proprietary set of more than 80,000 single-nucleotide polymorphisms used to locate disease genes across the human genome, with HealthChip®, a DNA diagnostic chip designed to place disease-associated SNPs on a single chip for clinical risk prediction.
The company monetizes this platform through the Clinical Outcomes Improvement Program (COIP®), a $200/year subscription service that applies optimized, FDA-approved generic ACE-inhibitor protocols to patients with diabetes, hypertension, and emphysema, with published claims of preventing ~90% of kidney failure and delaying emphysema progression. Complementary revenue streams include affiliate-marketer referral fees (10% of patient revenue; $15 average First-World, $1.50 Third-World referrals), free medical consultations via Skype, and prospective pharmaceutical drug-discovery partnerships targeting the ~2,500 causative genes GenoMed has identified for each of the six most common cancers since 2004.
Distribution is direct-to-consumer via the company website, a weekly WGNU 920 AM radio show ("To Your Health"), blog, Twitter, and free email/Skype consultations, supplemented by a global channel of independent retail pharmacies (Jennifer's Pharmacy in Missouri, Pharmacie Principale in Cameroon), a Philippines call-center partner (LaSalTech), and community-outreach points such as St. Louis barbershops. The company is private (it went private in March 2010 after the SEC suspended OTC trading in GMED.PK over delinquent filings), is headquartered in Leesburg, Florida, and has been financed primarily by its founder since around 2005, with no disclosed institutional investors or funding rounds.
Genomed firmographics
Firmographics- Name
- Genomed
- Legal name
- GenoMed, Inc.
- Website
- https://genomed.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- GenoMed is a US preventive-molecular-medicine company using its SNPnet® genomics platform and ACE-inhibitor protocols to deliver a $200/year COIP® subscription for patients with diabetes, hypertension, and emphysema, and to license disease-gene targets to pharmaceutical partners.
- Ownership category
- akta.pro rank
Where Genomed is headquartered
LocationHeadquarters
- HQ city
- Leesburg
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Genomed business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- Clinical Outcomes Improvement Program (COIP®) Subscription: Annual subscription program offering patients with diabetes, hypertension, and emphysema access to GenoMed's treatment protocols, ongoing monitoring, and superior clinical outcomes. Patients work with GenoMed physicians while maintaining their current doctor relationships.
- Marketing Referral Fees: GenoMed pays marketers 10% of patient revenues they generate. First World referral average is $15 per referral; Third World referral average is $1.50 per referral. The '10 + 10' campaign incentivizes patients and advocates to refer friends and family with chronic diseases.
- New Drug Discovery Partnerships: GenoMed pursues strategic alliances with large pharmaceutical companies to develop new drugs against identified disease gene targets. The company identifies disease genes and licenses or partners with pharma for drug development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Clinical Outcomes Improvement Program (COIP®) - Annual subscription for patients with diabetes, hypertension, or emphysema |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels8 records
Genomed product offering
Product offeringCore offering
GenoMed provides preventive molecular medicine by applying medical genomics to identify the genetic root causes of chronic diseases such as diabetes, hypertension, emphysema, and kidney disease. Its core commercial offering is the Clinical Outcomes Improvement Program (COIP®), an annual subscription service ($200/year) in which GenoMed physicians use proprietary ACE inhibitor treatment protocols and ongoing monitoring to deliver published superior clinical outcomes for patients with type 2 diabetes, hypertension, and COPD. The company also offers free medical consultations via Skype, repackages generic ACE inhibitors for new indications, and pursues pharmaceutical partnerships for new drug discovery.
Product overview
Genomed operates as a Next Generation Disease Management (DM™) company offering a portfolio of genomic medicine products and services. The core offering includes SNPnet©, a proprietary set of 80,000+ SNPs for identifying disease genes, and HealthChip®, a DNA-based diagnostic chip for clinical testing. The company provides the Clinical Outcomes Improvement Program (COIP®), a subscription-based service at $200/year, and Free Medical Advice™ consultations. Together, these products enable preventive molecular medicine targeting conditions like kidney failure, diabetes, hypertension, and cancer.
Differentiator
Problem solved
Functional benefit
Brands
- SNPnet: A set of single nucleotide polymorphisms (SNPs) used to locate disease genes, covering the entire human genome with over 80,000 SNPs.
- HealthChip
- COIP
Products and services
- Clinical Outcomes Improvement Program (COIP®) Annual subscription service providing genomics-based disease management for patients with type 2 diabetes, hypertension, and emphysema. Includes two months of intensive medication adjustment and ongoing monitoring using GenoMed's proprietary ACE inhibitor protocols. Marketed with a money-back guarantee of the best outcomes in the medical literature. Patients work with GenoMed physicians while maintaining their existing primary care doctor.
- Free Medical Advice™ Free medical consultation service offered to patients with chronic diseases including Parkinson's, chronic fatigue syndrome, emphysema, diabetes, cancer, and West Nile virus encephalitis. Delivered via Skype (ID: dwmoskowitz) and email, providing a top-of-funnel lead generation channel that converts patients into COIP® subscribers.
- Next Generation Disease Management (DM™) Comprehensive disease management service platform combining medical genomics with disease management. Includes developing better drugs, repurposing existing drugs for new indications, and providing gene-based diagnostic tests across the ACE-associated disease portfolio.
- SNPnet© A proprietary set of over 80,000 single nucleotide polymorphisms (SNPs) covering the entire human genome, used as a 'fishing' tool to locate disease genes and identify disease-associated genetic markers. Filed as a registered data asset.
- HealthChip® DNA diagnostic chip that places disease-associated SNPs onto a single chip for clinical diagnostic testing, particularly for predicting patients at high risk for particular diseases including cancers. Filed as pending IP.
- Cancer Clinical Trials Program Clinical trials offering novel non-toxic chemotherapy 'cocktails' for patients with any cancer at any stage, including leukemias and lymphomas. Approaches target host germline genes rather than tumor genetics, leveraging GenoMed's identified 2,500 causative genes per cancer type.
Quantifiable outcome
- 300% reduction in kidney disease progression rate in patients treated with optimized ACE inhibitor doses
- +3 more outcomes
Companies that use Genomed
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Genomed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Genomed partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered minor and core.
- Dame Shirley BasseyminorWorld-famous singer serving as GenoMed's first Patron. She lends her name to GenoMed's mission of preventive molecular medicine to increase global awareness. Patrons receive no shares or money from GenoMed. Dame Bassey embodies 'human royalty of merit, talent, beauty, determination, and graceful aging.'
- Jennifer's PharmacycoreIndependent retail pharmacy in Clayton, Missouri (suburb of St. Louis). Educates customers with diabetes, hypertension, and emphysema about GenoMed's COIP® program. Serves as point of contact for patient referrals. Address: 30 N Central Ave, Clayton, MO 63105. Contact: Jennifer Rich, R.Ph., (314) 862-7400.
- Safe Guard Medi-Systems Corporation (SGMS Corp)coreInventor of the portable electronic medical record (EMR) with distributors in Australia, South Africa, India, Canada, and the US. SGMS sells medi-chips in drugstores. Cross-promotional partner where GenoMed refers patients to SGMS for portable health records and vice versa.
- Pharmacie Principale (Kaya Holdings)coreIndependent retail pharmacy in Yaounde, capital of Cameroon, Central Africa. Educates customers about GenoMed's COIP® and Phase IV clinical trials. Operates telemedicine collaboration with GenoMed by email. CEO: Donald Njikam, PharmD. National law prevents pharmacy chains in Cameroon.
- LaSalTechcoreInternet company and call center in Bacolod, Philippines. Anchor partner for GenoMed-Filipino joint venture. LaSalTech introduced GenoMed to telecom partners, generic drug companies, and pharmacy chains. Chairman Brother Rolando Dizon is a trusted advisor to Philippine Presidents. First ISP in Bacolod, Negros Occidental.
- National Health Services (MyHealthyLifestyle.com)minoreHealth portal company launching updated MyHealthyLifestyle.com portal for wellness services and direct-to-consumer healthcare access. Partnership exposes NHS clients to GenoMed's diabetes, hypertension, and emphysema treatments. Contact: Elizabeth Gannon, President, 941-391-5991.
- The Mane EventminorSt. Louis barbershop (8327 Olive Blvd, St. Louis, MO 63132) partnering with GenoMed to place blood pressure monitors for customer health screening. Owner Gerald Shelton encourages customers to check blood pressure while waiting. Patients with BP over 120/80 are referred to GenoMed.
- Technical Medical Improvement (TMI)minorItalian company featuring GenoMed's Free Medical Advice campaign on its website. TMI is a leader in healthcare training tools and systems, operating within Italy and worldwide. Provides products in advanced medical training, healthcare communication, marketing solutions, and R&D.
- House of Lords Science and Technology CommitteeminorUK House of Lords Subcommittee on Genomic Medicine included GenoMed's contribution in a white paper encouraging the NHS to adopt genomic medicine advances. GenoMed provided input on ways patient populations could benefit from genomic medicine knowledge.
- ExL PharmaminorConference organizer for research pharmaceutical companies. GenoMed CEO Dr. Moskowitz chaired ExL Pharma's conference on model-based drug development in Philadelphia, January 2009. Conference attended by Merck, Johnson & Johnson, Bristol-Myers Squibb, Genzyme, Centocor, and FDA representatives.
- Offshore HRMminorMedical coding company with expertise in setting up call centers in India and Philippines. GenoMed committed to purchase Offshore HRM for restricted stock and cash. Would manage HIPAA-compliant patient communications and contribute coding revenue. COO Paula M. Hall, LVN, a former dialysis nurse.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Genomed competitors and assessment
Company assessmentDirect peers
- 23andMe: Consumer-facing genomics company that sells genetic risk reports directly to individuals. Compares to GenoMed as a direct-to-consumer genomics provider, though 23andMe focuses on risk prediction rather than treatment protocols.
- Human Longevity Inc. Precision health company combining whole-genome sequencing with phenotypic data to predict and prevent disease. Closely aligned with GenoMed's preventive molecular medicine thesis and population genomics approach.
- deCODE genetics: Iceland-based population genomics company that identifies disease-associated genes through population-scale genetic studies. Highly comparable approach to GenoMed's SNPnet disease-gene discovery strategy.
Broad incumbents
- Foundation Medicine: Genomic profiling company (now part of Roche) that uses next-generation sequencing to identify cancer-driving mutations. Comparable as a genomic profiling and precision medicine player, but focused on oncology and serving clinicians rather than consumers.
- Myriad Genetics: Established genetic testing company with hereditary cancer, pharmacogenomic, and molecular diagnostic tests. Comparable as a clinical genomics company translating gene-level insights into clinical decisions.
Emerging players
- Color Genomics: Genetics company offering hereditary cancer and heart disease screening at accessible price points. Comparable direct-to-consumer/employer-channel genetic testing business model.
- Helix: DNA sequencing platform offering consumer-facing genetic insights through partner apps. Comparable as a consumer genomics platform leveraging SNP-based disease risk information.
- Veritas Genetics: Whole-genome sequencing company offering individual risk reports including disease predispositions. Comparable direct-to-consumer genetic testing positioning with focus on disease prevention.
- Genomic Prediction: Genomic risk prediction company focused on clinical applications of polygenic risk scores. Adjacent genomics-based disease risk prediction player working in the preventive medicine space.
Others
- Intermountain Healthcare Precision Medicine: Large integrated delivery network investing in genomics-driven preventive care programs. Comparable as a payer/provider system seeking to use genetic information to prevent expensive downstream events like dialysis.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Genomed social profiles
Digital presenceGenomed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genomed leadership team
Management profileNumber of profiles
Profiles5 records
Genomed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genomed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genomed
What does Genomed do?
GenoMed provides preventive molecular medicine by applying medical genomics to identify the genetic root causes of chronic diseases such as diabetes, hypertension, emphysema, and kidney disease. Its core commercial offering is the Clinical Outcomes Improvement Program (COIP®), an annual subscription service ($200/year) in which GenoMed physicians use proprietary ACE inhibitor treatment protocols and ongoing monitoring to deliver published superior clinical outcomes for patients with type 2 diabetes, hypertension, and COPD. The company also offers free medical consultations via Skype, repackages generic ACE inhibitors for new indications, and pursues pharmaceutical partnerships for new drug discovery.
Is Genomed a public or private company?
Genomed is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Genomed founded?
Genomed was founded in 2001. It employs 1 to 10 people.
Where is Genomed based?
Genomed is headquartered in Leesburg, United States, in the North America region.
How does Genomed make money?
Three revenue lines are on record. Clinical Outcomes Improvement Program (COIP®) Subscription is the primary driver. The others are marketing Referral Fees and new Drug Discovery Partnerships.
Who are Genomed's main competitors?
Direct peers on record are 23andMe, Human Longevity Inc. and deCODE genetics. Broad incumbents are Foundation Medicine and Myriad Genetics. Emerging players are Color Genomics, Helix, Veritas Genetics and Genomic Prediction. Intermountain Healthcare Precision Medicine is listed as an others.
Does Genomed have an API?
No public API is recorded for Genomed.